Eli Lilly (LLY) Net Cash Flow (QoQ) (2009 - 2026)
Eli Lilly (LLY) Net Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.42% |
| Dec 31, 2025 | -138.48% |
| Sep 30, 2025 | 89,819.72% |
| Jun 30, 2025 | 102.31% |
| Mar 31, 2025 | -193.77% |
| Dec 31, 2024 | 501.72% |
| Sep 30, 2024 | -109.90% |
| Jun 30, 2024 | 354.88% |
| Mar 31, 2024 | -204.67% |
| Dec 31, 2023 | 196.71% |
| Sep 30, 2023 | 62.93% |
| Jun 30, 2023 | -159.18% |
| Mar 31, 2023 | 444.41% |
| Dec 31, 2022 | -22,121.05% |
| Sep 30, 2022 | -100.82% |
| Jun 30, 2022 | 116.73% |
| Mar 31, 2022 | -654.94% |
| Dec 31, 2021 | -54.50% |
| Sep 30, 2021 | 163.92% |
| Jun 30, 2021 | 132.43% |